Type 1 diabetes: using time-in-range to compare Gla-300 and IDeg-100
Key findings from the InRange study, comparing insulin glargine 300U/ml and insulin degludec 100U/ml in adults with type 1 diabetes, using a primary endpoint of time-in-range
You will learn:
• To understand the importance of time-in-range and its use as an endpoint in randomised controlled trials
• Key findings from the InRange study, comparing insulin glargine 300U/ml and insulin degludec 100U/ml in adults with type 1 diabetes, using a primary endpoint of time-in-range
To access this module, please register or login: